Moderna's combination skin cancer therapy receives FDA's breakthrough tag

Posted on:
Key Points

Feb 22 (Reuters) - Moderna Inc (MRNA.O) said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's (MRK.N) drug Keytruda has received breakthrough therapy designation from U.S.

Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44% compared with Keytruda alone.

The FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition.

Full story at Reuters | 

You might be interested in

Moderna, Merck begin late-stage study for mRNA cancer therapy

11, Dec, 23

Moderna (MRNA.O) and Merck & Co (MRK.N) said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.

Read at Reuters Key Points

Merck's lung cancer drug combo fails to meet trial goal

07, Dec, 23

Merck (MRK.N) said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study.

Read at Reuters Key Points

First UK patients receive experimental messenger RNA cancer therapy

04, Feb, 24

The British clinical trial of the revolutionary new mRNA treatment will test its effectiveness in combating a range of cancers

Read at the Guardian Key Points

Cognitive behavioural therapy may help boost mental health of cancer survivors

24, Aug, 24

Results of the study have important clinical ramifications, especially for supportive oncology professionals

Read at The Tribune Key Points

Modifying chemotherapy treatment can improve lives of older people with cancer

22, Feb, 24

The study shows that standard chemotherapy regimens can be harmful to older persons with cancer because of their other health conditions. | Health

Read at Hindustan Times Key Points

AbbVie's blood cancer combo therapy fails in late-stage study

29, Sep, 23

AbbVie (ABBV.N) said on Friday a late-stage study of its experimental combination therapy to treat a form of blood cancer failed to meaningfully increase the survival rate of patients without the disease worsening.

Read at Reuters Key Points

How antibacterial treatment helps in skin problem caused by radiation therapy

07, May, 23

The study shows how a common skin bacteriym in ARD cases has shown affordable treatment for patients receiving radiation therapy. | Health

Read at Hindustan Times Key Points

US FDA approves AstraZeneca's breast cancer drug combination

17, Nov, 23

The U.S. Food and Drug Administration on Thursday approved AstraZeneca's (AZN.L) Truqap in combination with an older drug, providing another treatment option for patients with the most common type of breast cancer.

Read at Reuters Key Points

Lung cancer pill cuts risk of death by half, says ‘thrilling’ study

04, Jun, 23

Taking the drug osimertinib once a day after surgery reduces chance of patients dying by 51%, trials show

Read at the Guardian Key Points